Federal Judge Blocks Pentagon's Blacklisting of AI Company Anthropic 
Apple Turns 50: From Garage Startup to AI Crossroads 
BlackRock CEO Larry Fink Earns $37.7 Million in 2025 Amid Record Growth 
Jefferies Upgrades Sodexo to Buy With €55 Target After Historic CEO Appointment 
Annie Altman Amends Sexual Abuse Lawsuit Against OpenAI CEO Sam Altman 
Star Entertainment Secures $390M Refinancing Deal to Stabilize Operations 
KPMG UK Cuts 440 Audit Jobs Amid Low Attrition and Cooling Professional Services Demand 
Novartis to Acquire Biotech Firm Excellergy in $2 Billion Deal 
Cybersecurity Stocks Tumble After Anthropic's Claude Mythos AI Leak Sparks Market Fears 
SpaceX Eyes Historic IPO at $1.75 Trillion Valuation 
Fonterra Admits Anchor Butter "Grass-Fed" Label Misled Consumers After Greenpeace Lawsuit 
TSMC Japan's Second Fab to Produce 3nm Chips by 2028 
Nike Beats Q3 Estimates but China Weakness and Margin Pressure Weigh on Outlook 
Norma Group Posts Revenue Decline in 2025, Eyes Modest Recovery in 2026 
SoftwareONE Posts 22.5% Revenue Surge in 2025 on Crayon Acquisition 
Cathay Pacific Holds Firm on Flight Capacity Amid Middle East Conflict and Rising Fuel Costs 
CTOC Adds 3,000 Doctors, 500 Hospitals Ahead of Liquidity Push 
PLAINSBORO, N.J., Dec. 22, 2016 -- Integra LifeSciences Holdings Corporation (NASDAQ:IART) today announced that its stockholders approved a two-for-one stock split and an increase from 60 million to 240 million authorized shares of the Company’s common stock at a special meeting of stockholders held on Wednesday, December 21, 2016.
Holders of record, as of the close of markets on December 21, 2016, will be entitled to receive one additional share of common stock for each share held. The shares are expected to be distributed on January 3, 2017. The adjusted stock price is expected to be reflected on the NASDAQ stock market on January 4, 2017.
About Integra LifeSciences
Integra LifeSciences Holdings Corporation, a world leader in medical technology, is dedicated to limiting uncertainty for clinicians, so they can concentrate on providing the best patient care. Integra offers innovative solutions, including leading plastic and regenerative technologies, in specialty surgical solutions, orthopedics and tissue technologies. For more information, please visit www.integralife.com.
Statements made at the upcoming conferences may be forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve risks and uncertainties that could cause actual results to differ from predicted results. Forward-looking factors that may be discussed include, but are not limited to, future financial performance, new product development, governmental approvals, market potential and resulting sales as well as potential therapeutic applications, and additional acquisitions. These risks and uncertainties include market conditions and other factors beyond the Company's control and the economic, competitive, governmental, technological and other factors identified under the heading "Risk Factors" included in item 1A of Integra's Annual Report on Form 10-K for the year ended December 31, 2015 and information contained in subsequent filings with the Securities and Exchange Commission could affect actual results. These forward-looking statements are made only as the date thereof, and the Company undertakes no obligation to update or revise the forward-looking statements, whether as a result of new information, future events or otherwise.
Contacts: Integra LifeSciences Holdings Corporation Investor Relations: Angela Steinway (609) 936-2268 [email protected] Michael Beaulieu (609) 750-2827 [email protected]
